Company intelligence / Profile preview

Chase Therapeutics

Washington, DC, United Stateschasetherapeutics.com ↗

Ownership: Private
Development stage: Other

Overview

Chase Therapeutics is advancing two lead drug candidates—CTC-501 for Major Depressive Disorder and CTC-413 for Parkinson’s Disease—both entering or preparing for Phase 3 pivotal trials. CTC-501 has shown rapid symptomatic relief in MDD with good tolerability, while CTC-413 demonstrated effective symptom mitigation and neuroprotective potential in proof-of-concept trials. The company is also developing a novel diagnostic tool to improve early detection of Parkinson's Disease.

Therapeutic areas: PsychiatryNeurology
Modalities: Small moleculesDiagnostic products (for Parkinson’s Disease)
Industry: Biotech

Partnerships

Chinalink Asia Holdings led Series B financing round; no major pharma partnerships disclosed but investors include Brain Trust Accelerator Fund II, Rise of the Rest Fund, Makana Holdings.

Beyond the preview

Go deeper on Chase Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Chase Therapeutics.